Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Codexis Inc Stock Research

CDXS

1.61USD-0.09(-5.29%)Market Closed
Watchlist

Market Summary

USD1.61-0.09
Market Closed
-5.29%

CDXS Alerts

  • 4 major insider buys recently.

CDXS Stock Price

CDXS RSI Chart

CDXS Valuation

Market Cap

112.4M

Price/Earnings (Trailing)

-1.98

Price/Sales (Trailing)

1.13

EV/EBITDA

-0.4

Price/Free Cashflow

-18.59

CDXS Price/Sales (Trailing)

CDXS Profitability

EBT Margin

-40.93%

Return on Equity

-37.97%

Return on Assets

-21.94%

Free Cashflow Yield

-5.38%

CDXS Fundamentals

CDXS Revenue

Revenue (TTM)

99.2M

Revenue Y/Y

-44.48%

Revenue Q/Q

64.25%

CDXS Earnings

Earnings (TTM)

-56.7M

Earnings Y/Y

-336.48%

Earnings Q/Q

49.05%

Price Action

52 Week Range

1.586.98
(Low)(High)

Last 7 days

-19.4%

Last 30 days

-1.7%

Last 90 days

-38.2%

Trailing 12 Months

-74.9%

CDXS Financial Health

Current Ratio

3.39

CDXS Investor Care

Shares Dilution (1Y)

6.92%

Diluted EPS (TTM)

-0.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CDXS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-11
Norrett Kevin
bought
15,479
1.7199
9,000
chief operating officer
2023-09-08
Ryali Sriram
bought
19,856
1.7044
11,650
chief financial officer
2023-09-08
DILLY STEPHEN GEORGE
bought
100,952
1.7263
58,479
see remarks
2023-09-08
Fitzgerald Margaret Nell
bought
20,064
1.6955
11,834
see remarks
2023-06-13
Singhvi Rahul
acquired
-
-
34,602
-
2023-06-13
Aaker Jennifer
acquired
-
-
34,602
-
2023-06-13
PARKER H STEWART
acquired
-
-
34,602
-
2023-06-13
WOLF DENNIS P
acquired
-
-
34,602
-
2023-06-13
Smith David V
acquired
-
-
34,602
-
2023-06-13
Dorgan Byron L
acquired
-
-
34,602
-

1–10 of 50

Which funds bought or sold CDXS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-4.22
-1,278
2,352
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-70.27
-246,730
62,110
-%
2023-08-18
Legato Capital Management LLC
sold off
-100
-468,872
-
-%
2023-08-16
Nuveen Asset Management, LLC
added
8.26
-1,845,160
5,044,840
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
34.49
-30,634
308,308
-%
2023-08-15
Miller Investment Management, LP
unchanged
-
-15,669
32,740
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
1,005
406,343
469,109
-%
2023-08-15
CAPTRUST FINANCIAL ADVISORS
new
-
29,352
29,352
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
3.7
-361,567
849,047
-%
2023-08-15
CAXTON ASSOCIATES LP
unchanged
-
-39,022
81,539
0.01%

1–10 of 49

Latest Funds Activity

Are funds buying CDXS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CDXS
No. of Funds

Schedule 13G FIlings of Codexis

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 08, 2023
blackrock inc.
10.4%
6,932,344
SC 13G/A
Feb 14, 2023
nantahala capital management, llc
6.8%
4,487,782
SC 13G/A
Feb 14, 2023
casdin capital, llc
0%
0
SC 13G/A
Feb 10, 2023
ark investment management llc
6.00%
3,941,985
SC 13G/A
Feb 09, 2023
vanguard group inc
5.54%
3,642,208
SC 13G/A
Jan 24, 2023
blackrock inc.
9.4%
6,154,933
SC 13G/A
Jan 18, 2023
baillie gifford & co
9.46%
6,210,551
SC 13G/A
Feb 09, 2022
vanguard group inc
5.24%
3,400,490
SC 13G
Feb 09, 2022
ark investment management llc
5.00%
3,244,040
SC 13G/A
Feb 03, 2022
blackrock inc.
7.9%
5,144,949
SC 13G/A

Recent SEC filings of Codexis

View All Filings
Date Filed Form Type Document
Sep 12, 2023
4
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 07, 2023
8-K
Current Report
Aug 08, 2023
SC 13G/A
Major Ownership Report
Aug 03, 2023
S-8
Employee Benefits Plan
Aug 03, 2023
10-Q
Quarterly Report
Aug 03, 2023
8-K
Current Report
Aug 03, 2023
S-8
Employee Benefits Plan

Peers (Alternatives to Codexis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
32.2B
7.0B
-5.38% -12.23%
28.38
4.6
5.03% -14.68%
23.9B
4.0B
-3.30% -3.12%
26.91
6.05
2.30% 16.37%
21.1B
4.5B
-17.36% -28.94%
-5.03
4.72
-4.92% -21931.58%
11.0B
1.1B
-9.93% -5.35%
38.64
9.7
2.81% 4.86%
MID-CAP
9.4B
134.2M
4.73% -21.54%
68.08
70.03
-82.77% -13.43%
SMALL-CAP
2.3B
146.1M
-8.89% 61.75%
-7.06
15.43
4.72% -55.19%
960.9M
112.0M
5.18% 169.83%
-14.6
8.58
0.83% 16.42%
749.3M
189.6M
-19.57% -31.57%
-3.92
3.95
18.74% 17.75%
175.9M
114.1M
-1.44% 44.37%
-32.4
1.54
-5.49% -48.58%
112.4M
99.2M
-1.73% -74.89%
-1.98
1.13
-26.56% -199.52%
104.0M
80.9M
-10.97% -2.13%
-16.02
1.29
17.20% 77.07%
99.1M
31.5M
-1.32% 40.85%
-0.68
3.14
35.12% -38.47%
71.9M
52.7M
-20.39% -41.08%
-9.51
1.36
2.10% -1984.29%
68.4M
143.9M
-41.73% -89.43%
-0.41
0.48
0.71% -18.99%

Codexis News

InvestorsObserver
Is Codexis, Inc. (CDXS) a Winner in the Biotechnology Industry?.
InvestorsObserver,
2 days ago
Marketscreener.com
Clayton County Register
Securities.io
Insider Monkey

Returns for CDXS

Cumulative Returns on CDXS

-0.3%


10-Year Cumulative Returns

-12.1%


7-Year Cumulative Returns

-37.6%


5-Year Cumulative Returns

-48.1%


3-Year Cumulative Returns

Risks for CDXS

What is the probability of a big loss on CDXS?

99.6%


Probability that Codexis stock will be more than 20% underwater in next one year

79.2%


Probability that Codexis stock will be more than 30% underwater in next one year.

63.9%


Probability that Codexis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CDXS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Codexis was unfortunately bought at previous high price.

Drawdowns

Financials for Codexis

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-14.7%99,150,000116,233,000138,590,000132,717,000135,016,000122,063,000104,754,000101,287,00082,903,00072,417,00069,056,00066,672,00070,193,00067,545,00068,458,00065,876,00060,916,00062,135,00060,594,00066,249,00059,287,000
Operating Expenses----------------78,123,00075,528,00073,962,00071,889,00076,020,00076,988,000
  S&GA Expenses5.2%54,576,00051,867,00052,172,00051,583,00051,491,00053,630,00049,323,00046,342,00041,732,00037,459,00035,049,00033,630,00032,702,00032,076,00031,502,00030,986,00030,461,00029,960,00029,291,00030,352,00030,997,000
  R&D Expenses-2.3%75,499,00077,254,00080,099,00076,767,00070,111,00063,848,00055,919,00049,917,00046,762,00044,789,00044,185,00042,703,00039,404,00036,825,00033,873,00032,515,00031,721,00030,817,00029,978,00031,882,00032,020,000
EBITDA100.0%--41,881,000-27,880,000-26,024,000-14,330,000-16,687,000-17,963,000-12,148,000-20,834,000-24,047,000-22,627,000-19,349,000-12,942,000-13,409,000-10,877,000------
EBITDA Margin100.0%--0.36-0.20-0.20-0.11-0.14-0.17-0.12-0.25-0.33-0.33-0.29-0.18-0.20-0.16------
Interest Expenses-11.1%32,00036,00034,00030,00023,00016,00014,00043,00051,00051,00052,00048,00044,00031,00049,00039,00051,00084,00084,00071,00069,333
Earnings Before Taxes-18.9%-56,552,000-47,570,000-33,316,000-30,985,000-18,647,000-20,372,000-21,090,000-14,881,000-23,310,000-25,090,000-23,671,000-20,389,000-13,978,000-14,432,000-11,918,000-11,775,000-14,098,000-11,353,000-10,915,000-9,510,000-17,599,000
EBT Margin100.0%--0.41-0.24-0.23-0.14-0.17-0.20-0.15-0.28-0.35-0.34-0.31-0.20-0.21-0.17------
Net Income-18.6%-56,736,000-47,853,000-33,592,000-31,178,000-18,942,000-20,567,000-21,279,000-15,009,000-23,347,000-25,426,000-24,010,000-20,725,000-14,288,000-14,451,000-11,935,000-11,761,000-14,092,000-11,320,000-10,878,000-9,447,000-17,685,000
Net Income Margin100.0%--0.41-0.24-0.23-0.14-0.17-0.20-0.15-0.28-0.35-0.35-0.31-0.20-0.21-0.17------
Free Cashflow-100.0%-7,501,0002,977,000-6,793,000-29,413,000-35,380,000-28,095,000-26,255,000-26,303,000-27,016,000-20,212,000-21,308,000-20,111,000-15,180,000-16,290,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-5.2%20721825023523523524622821221222213814214914914614710179.0079.0076.00
  Current Assets-7.6%12013016314614514516217417217418410310611511411011064.0068.0068.0066.00
    Cash Equivalents-10.4%92.0010311410990.0094.0011911913014014972.0076.0087.0092.0092.0093.0047.0054.0054.0054.00
  Inventory2.8%2.002.002.002.002.002.001.001.001.001.001.001.001.001.000.000.001.001.001.001.001.00
  Net PPE-1.2%23.0024.0023.0023.0024.0023.0021.0016.0011.0010.0010.007.007.007.006.006.005.005.005.005.004.00
  Goodwill0%3.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00
Liabilities-10.2%83.0092.0010681.0076.0077.0082.0058.0050.0048.0052.0047.0047.0050.0044.0044.0048.0050.0023.0024.0023.00
  Current Liabilities-6.7%36.0038.0049.0032.0030.0029.0033.0033.0024.0023.0025.0020.0019.0022.0015.0015.0017.0019.0018.0018.0016.00
    LT Debt, Non Current--------------------0.000.00
Shareholder's Equity-1.5%12412614515415915916416916316417091.0095.0099.0010610399.0051.0056.0055.0053.00
  Retained Earnings-2.6%-455-443-421-408-398-396-387-377-379-375-366-362-356-350-342-341-342-335-330-330-328
  Additional Paid-In Capital1.7%580570566563558555552547543539537453451449448444441387387385381
Shares Outstanding4.7%70.0067.0066.0066.0065.0065.0065.0065.0064.0064.0064.0059.0059.0059.0059.0058.0055.0054.0052.0054.0053.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-104.9%-64813,25811,2847,027-12,899-19,013-14,267-16,419-19,701-21,479-16,464-18,633-16,149-11,134-12,560-9,619-9,862-12,760-14,094-5,748-9,365
  Share Based Compensation-3.8%12,98713,50214,53114,64613,13112,74411,59310,1839,1518,2467,7287,2527,0007,0496,9437,4657,5037,9727,8898,0868,149
Cashflow From Investing9.6%-6,131-6,780-13,578-19,091-28,779-28,971-21,422-18,430-8,203-7,520-5,748-3,674-4,898-3,981-3,665-3,944-2,551-3,195-2,766-2,318-1,778
Cashflow From Financing325.2%8,7472,057-5751,5122,2472,4703,76782,92782,18481,84480,8081,6443,20755,02453,96151,79052,50239,25138,56938,35135,831

CDXS Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 21,323$ 38,406$ 34,305$ 73,746
Costs and operating expenses:    
Cost of product revenue3,17811,2707,69819,791
Research and development17,33419,08933,98838,590
Selling, general and administrative13,36510,65628,76526,360
Restructuring charges7201450
Total costs and operating expenses33,94941,01570,59684,741
Loss from operations(12,626)(2,609)(36,291)(10,995)
Interest income1,1211402,209182
Other expense, net(9)(63)(33)(66)
Loss before income taxes(11,514)(2,532)(34,115)(10,879)
Provision for income taxes910825117
Net loss$ (11,523)$ (2,640)$ (34,140)$ (10,996)
Net loss per share, basic (in dollars per share)$ (0.17)$ (0.04)$ (0.51)$ (0.17)
Net loss per share, diluted (in dollars per share)$ (0.17)$ (0.04)$ (0.51)$ (0.17)
Weighted average common stock shares used in computing net loss per share, basic (in shares)67,57365,28866,75665,193
Weighted average common stock shares used in computing net loss per share, diluted (in shares)67,57365,28866,75665,193
Product revenue    
Revenues:    
Total revenues$ 11,048$ 34,645$ 19,412$ 65,335
Research and development revenue    
Revenues:    
Total revenues$ 10,275$ 3,761$ 14,893$ 8,411

CDXS Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 92,093$ 113,984
Restricted cash, current524521
Financial assets:  
Accounts receivable8,80631,904
Contract assets2,2482,116
Unbilled receivables10,6917,016
Total financial assets21,74541,036
Less: allowances(133)(163)
Total financial assets, net21,61240,873
Inventories2,0522,029
Prepaid expenses and other current assets3,7635,487
Total current assets120,044162,894
Restricted cash1,5301,521
Investment in non-marketable equity securities ($0 and $13,921 with a related party)21,37820,510
Right-of-use assets - Operating leases, net36,74539,263
Property and equipment, net23,32522,614
Goodwill3,2413,241
Other non-current assets498350
Total assets206,761250,393
Current liabilities:  
Accounts payable4,0423,246
Accrued compensation8,53811,453
Other accrued liabilities7,00115,279
Current portion of lease obligations - Operating leases5,6265,360
Deferred revenue10,52913,728
Total current liabilities35,73649,066
Deferred revenue, net of current portion10,11016,881
Long-term lease obligations - Operating leases35,37938,278
Other long-term liabilities1,4051,371
Total liabilities82,630105,596
Commitments and Contingencies (Note 10)
Stockholders' equity:  
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding00
Common stock, $0.0001 par value per share; 100,000 shares authorized; 69,804 shares and 65,811 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively66
Additional paid-in capital579,555566,081
Accumulated deficit(455,430)(421,290)
Total stockholders' equity124,131144,797
Total liabilities and stockholders' equity$ 206,761$ 250,393
John J. Nicols
260
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.